| Authors: |
Haas EJ; Public Health Services, Jerusalem, Israel; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel., McLaughlin JM; Pfizer, Collegeville, PA, USA., Khan F; Pfizer, Collegeville, PA, USA., Angulo FJ; Pfizer, Collegeville, PA, USA., Anis E; Public Health Services, Jerusalem, Israel; Hadassah Braun School of Public Health, Faculty of Medicine, Hebrew University, Jerusalem, Israel., Lipsitch M; Faculty of Medicine Harvard T H Chan School of Public Health, Boston, MA, USA., Singer SR; Public Health Services, Jerusalem, Israel; Hadassah Braun School of Public Health, Faculty of Medicine, Hebrew University, Jerusalem, Israel., Mircus G; Pfizer Pharmaceuticals Israel, Herzliya, Israel., Brooks N; Information Technology Department, Israel Ministry of Health, Jerusalem, Israel., Smaja M; Information Technology Department, Israel Ministry of Health, Jerusalem, Israel., Pan K; Pfizer, Collegeville, PA, USA., Southern J; Pfizer, Collegeville, PA, USA., Swerdlow DL; Pfizer, Collegeville, PA, USA., Jodar L; Pfizer, Collegeville, PA, USA., Levy Y; Israel Ministry of Health, Jerusalem, Israel., Alroy-Preis S; Public Health Services, Jerusalem, Israel. Electronic address: sharon.alroy@moh.gov.il. |
